Stahl, Maximilian
Shallis, Rory M. http://orcid.org/0000-0002-8542-2944
Wei, Wei
Montesinos, Pau http://orcid.org/0000-0002-3275-5593
Lengline, Etienne
Neukirchen, Judith
Bhatt, Vijaya R.
Sekeres, Mikkael A.
Fathi, Amir T.
Konig, Heiko
Luger, Selina http://orcid.org/0000-0003-3364-4366
Khan, Irum
Roboz, Gail J.
Cluzeau, Thomas
Martínez-Cuadron, David
Raffoux, Emmanuel
Germing, Ulrich
Umakanthan, Jayadev Manikkam
Mukherjee, Sudipto
Brunner, Andrew M. http://orcid.org/0000-0002-2169-4115
Miller, Adam
McMahon, Christine M.
Ritchie, Ellen K.
Rodríguez-Veiga, Rebeca
Itzykson, Raphaël http://orcid.org/0000-0003-2139-6262
Boluda, Blanca
Rabian, Florence
Tormo, Mar
Acuña-Cruz, Evelyn
Rabinovich, Emma
Yoo, Brendan
Cano, Isabel
Podoltsev, Nikolai A. http://orcid.org/0000-0002-3657-778X
Bewersdorf, Jan Philipp http://orcid.org/0000-0003-3352-0902
Gore, Steven
Zeidan, Amer M.
Article History
Received: 18 November 2019
Revised: 17 February 2020
Accepted: 19 February 2020
First Online: 4 March 2020
Compliance with ethical standards
:
: MS: no relevant financial relationship(s) to disclose. RMS: no relevant financial relationship(s) to disclose. WW: no relevant financial relationship(s) to disclose. PM<b>:</b> Daiichi Sankyo: Consultancy and Speakers Bureau. Novartis: Research Funding and Speakers Bureau. EL: No relevant financial relationship(s) to disclose. JN: no relevant financial relationship(s) to disclose. VRB<b>:</b> consulting fees: CSL Behring, Agios, Abbvie, Partner therapeutics and Incyte. Research funding: Jazz, Incyte, Tolero Pharmaceuticals, Inc, and National Marrow Donor Program. MAS<b>:</b> no relevant financial relationship(s) to disclose. ATF<b>:</b> consulting/advisory board—Celgene, Takeda, Abbvie, Forty seven, NewLink, Trovagene, Pfizer, Daiichi Sankyo, Astellas, Amphivena. Clinical trial funding—Celgene and Agios. HK<b>:</b> no relevant financial relationship(s) to disclose. SL<b>:</b> no relevant financial relationship(s) to disclose. IK<b>:</b> Teva: Speakers Bureau. GJR<b>:</b> AbbVie: Consultancy. Amphivena Therapeutics: Consultancy. Argenx: Consultancy. Astex Pharmaceuticals: Consultancy. Bayer: Consultancy. Celgene Corporation: Consultancy. Celltrion: Consultancy. Daiichi Sankyo: Consultancy. Bayer: Consultancy. Eisai: Consultancy. Janssen Pharmaceuticals: Consultancy. Jazz Pharmaceuticals: Consultancy. Novartis: Consultancy. Daiichi Sankyo: Consultancy. Orsenix: Consultancy. Otsuka: Consultancy. Eisai: Consultancy. Pfizer: Consultancy. Roche/Genentech: Consultancy. Sandoz: Consultancy. Cellectis: Research Funding. Orsenix: Consultancy. TC<b>:</b> Celgene: Consultancy, Membership on an entity’s Board of Directors or advisory committees and Speakers. Bureau. Menarini: Consultancy. Jazz Pharma: Consultancy, Membership on an entity’s Board of Directors or advisory committees and Speakers Bureau. Amgen: Membership on an entity’s Board of Directors or advisory committees and Speakers Bureau. AbbVie: Membership on an entity’s Board of Directors or advisory committees and Speakers Bureau. Sanofi: Speakers Bureau. Pfizer: Speakers Bureau. DMC: no relevant financial relationship(s) to disclose. ER<b>:</b> no relevant financial relationship(s) to disclose. UG: Celgene: Honoraria, Research Funding and Consultancy. Novartis: Honoraria and Research Funding. Janssen: Honoraria. JMU<b>:</b> no relevant financial relationship(s) to disclose. SM: Aplastic Anemia & MDS International Foundation in Joint Partnership with Cleveland Clinic Taussig Cancer Institute: Honoraria. BioPharm Communications: Consultancy. Bristol Myers Squib: Honoraria and Speakers Bureau. LEK Consulting: Consultancy and Honoraria. Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees and Research Funding. Pfizer: Honoraria. Projects in Knowledge: Honoraria. Takeda: Membership on an entity’s Board of Directors or advisory committees. AMB: Takeda: Research Funding. Celgene: Consultancy and Research Funding. Novartis: Research Funding. AMM<b>:</b> no relevant financial relationship(s) to disclose CMM: no relevant financial relationship(s) to disclose. EKR: Incyte: Consultancy and Speakers Bureau. Celgene: Consultancy, Other: Travel, Accommodations, Expenses and Speakers Bureau. Pfizer: Consultancy and Research Funding. Novartis: Consultancy, Other: Travel, Accommodations, Expenses, Research Funding and Speakers Bureau. ARIAD Pharmaceuticals: Speakers Bureau. Astellas Pharma: Research Funding. Bristol Myers Squibb: Research Funding. NS Pharma: Research Funding. RRV: no relevant financial relationship(s) to disclose. RI<b>:</b> no relevant financial relationship(s) to disclose. BB<b>:</b> No relevant financial relationship(s) to disclose. FR: no relevant financial relationship(s) to disclose. MT<b>:</b> no relevant financial relationship(s) to disclose. EGAC: no relevant financial relationship(s) to disclose. ER: no relevant financial relationship(s) to disclose. BY<b>:</b> no relevant financial relationship(s) to disclose. IC: no relevant financial relationship(s) to disclose. NAP: Agios Pharmaceuticals: Consultancy and Honoraria. Astellas Pharma: Research Funding. Blueprint Medicines: Consultancy and Honoraria. Incyte: Consultancy and Honoraria. Novartis: Consultancy and Honoraria. Boehringer-Ingelheim: Research Funding. Daiichi Sankyo: Research Funding. Sunesis Pharmaceuticals: Research Funding. Celator: Research Funding. Pfizer: Research Funding, Consultancy and Honoraria. Astex Pharmaceuticals: Research Funding. Celgene: Research Funding, Consultancy and Honoraria. Genentech: Research Funding. AI Therapeutics: Research Funding. Samus Therapeutics: Research Funding. Arog Pharmaceuticals: Research Funding. Kartos Therapeutics: Research Funding. JPB: no relevant financial relationship(s) to disclose. SDG<b>:</b> Celgene: Consultancy and Research Funding. AMZ received research funding from Celgene, Acceleron, Abbvie, Otsuka, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Trovagene, Incyte, Takeda, Novartis, Aprea, Astex, and ADC Therapeutics. AMZ had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene, Jazz, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Seattle Genetics, BeyondSpring, Trovagene, Takeda, Ionis, and Epizyme. AMZ received travel support for meetings from Pfizer, Novartis, and Trovagene. None of these relationships were related to the development of this paper.